Custom Search

Rituximab News

Cancer Drug Slows Multiple Sclerosis Progression

Two shots of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly a year, researchers reported on Wednesday.

Role of Mitoxantrone in Combination Therapy for Chronic Lymphocytic Leukemia (CLL) Evaluated

Researchers from Spain have reported preliminary results of initial treatment of patients with chronic lymphocytic leukemia (CLL) with a combination of RituxanŽ (rituximab), FludaraŽ (fludarabine), CytoxanŽ (cyclophosphamide) and...

Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate

Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan(R) (rituximab) in biologic-naive patients met its primary endpoint of a significantly greater proportion of...

MabThera(REG) Helps Patients With Lymphoma Stay Symptom Free And Live Longer

A study published recently in Blood, the journal of the American Society of Hematology, has confirmed that patients who receive MabThera as maintenance therapy for lymphoma experience significantly longer remission and overall...

FDA Issues Safety Warning On Biogen Drug; Stock Is Falling

Monday, the U.S. Food and Drug Administration or FDA issued a warning to healthcare professionals and patients treated with Rituxan or rituximab about the risk of a serious side effect in patients who were administered the drug....

Displaying results 1 to 5 out of 24






Next >

Use of this site is subject to the following terms of use